BioSpace News Archive

Pharm Country

Renowned Pulmonary Wellness & Rehabilitation Center to Launch Online Wellness Program to Help Enrich Quality of Life for Respiratory Patients

The Pulmonary Wellness & Rehabilitation Center, now in its 21st year of providing the highest quality and most expertly delivered patient experience in Pulmonary Wellness, is launching a new 6-week Pulmonary Wellness Online Boot Camp.

October 10, 2018
·
4 min read
Biotech Bay

OCREVUS (Ocrelizumab) Data Show Early Initiation of Treatment Reduces Disability Progression Over Five Years in Relapsing and Primary Progressive Multiple Sclerosis

People with relapsing MS (RMS) treated sooner with OCREVUS had earlier reduction in disease activity and less disability progression vs. those who switched from interferon beta-1α

October 10, 2018
·
14 min read
Business

TopAlliance and UTHealth Sign a Patent and Technology License Agreement

Access Novel Antibody Technology

October 10, 2018
·
2 min read
Business

Gurulogic Microsystems: Hamburger Mogul’s Quest for a World-Changing Codec

Heikki Salmela is best known as the owner and founder of the multi-national hamburger chain Hesburger.

October 10, 2018
·
2 min read
One in four Canadian physicians report burnout

New CMA survey provides key indicators on physician health

October 10, 2018
·
2 min read
Business

GB Sciences’ CEO John Poss and Chief Science Officer Dr. Andrea Small-Howard Featured at Digital Hollywood’s California Cannabis Forum in Los Angeles

Mr. Poss will speak on GB Sciences’ collaboration with Native Americans in California; Dr. Small-Howard will discuss research to address specific diseases using cannabinoids.

October 10, 2018
·
4 min read
Business

Tango Therapeutics Appoints Malte Peters, MD, to Board of Directors

Tango Therapeutics today announced the appointment of Malte Peters, MD, to its board of directors.

October 10, 2018
·
2 min read
Drug Development

Alphamab Oncology’s first-in-class PD-L1 - CTLA-4 bispecific antibody enters clinical trial

Alphamab Oncology announced that its proprietary humanized PD-L1 - CTLA-4 bispecific antibody (product code: KN046) program, the first of its class, has recently started phase I clinical trial in Australia.

October 10, 2018
·
2 min read
Pharm Country

New analysis estimates the positive impact of Jardiance® on life expectancy in adults with type 2 diabetes and established cardiovascular disease

Survival estimates from the EMPA-REG OUTCOME® trial data demonstrate potential long-term benefit of Jardiance (empagliflozin) on life expectancy of adults with type 2 diabetes and cardiovascular disease

October 10, 2018
·
12 min read
Drug Development

TapImmune’s HER2/neu-Targeted Breast Cancer Vaccine to be Studied in a Large Phase 2 Immunotherapy Combination Study Funded by an $11 Million U.S. Department of Defense Grant

Mayo Clinic Receives $11 Million to Study TPIV110 in Combination with Trastuzumab (Herceptin®)

October 10, 2018
·
4 min read